Ordered to be Reported by the Yeas and Nays: 38 - 7.
The bill creates a temporary (2026–2030) exception to the physician self‑referral (Stark) prohibition allowing physicians or their group practices to dispense certain Medicare Part D outpatient prescription drugs directly to patients under specified conditions. It requires an in‑person patient relationship and recent face‑to‑face encounter, permits in‑person pickup or delivery, and requires billing by the physician/group or a wholly owned entity.
Access and convenience versus conflict‑of‑interest and cost concerns
Relative to its intended legislative type, this bill is a clearly drafted substantive amendment that establishes a time-limited exception to the physician self-referral prohibition for certain Part D drugs, with detailed eligibility conditions and a mandated GAO study.
The bill creates a temporary (2026–2030) exception to the physician self‑referral (Stark) prohibition allowing physicians or their group practices to dispense certain Medicare Part D outpatient prescription drugs directly to patients under specified conditions.
It requires an in‑person patient relationship and recent face‑to‑face encounter, permits in‑person pickup or delivery, and requires billing by the physician/group or a wholly owned entity.
The bill directs the Comptroller General (GAO) to study and report within three years on pharmacies and physician‑linked dispensing arrangements and their characteristics.
Technically specific and time‑limited, improving prospects, but contested interests and uncertain fiscal impacts reduce overall likelihood.
Relative to its intended legislative type, this bill is a clearly drafted substantive amendment that establishes a time-limited exception to the physician self-referral prohibition for certain Part D drugs, with detailed eligibility conditions and a mandated GAO study. It integrates with existing statutory definitions and contains concrete operational criteria.
Access and convenience versus conflict‑of‑interest and cost concerns
These are examples from the analysis, not a ranked list of the most-affected groups.
Access and convenience versus conflict‑of‑interest and cost concerns
Likely cautious to skeptical.
Supporters would note improved access for seniors, but progressives will worry this creates financial incentives to favor in‑office dispensing over lower‑cost options.
The GAO study is welcome but may be seen as insufficient without stronger upfront safeguards and transparency requirements.
Pragmatic, generally supportive but cautious.
Sees access and continuity benefits for seniors and values the sunset and GAO study as guardrails.
Wants measurable metrics and anti‑fraud monitoring to limit unintended spending increases.
Mixed to somewhat opposed.
Values improved access and practice flexibility, but is concerned about expanding an exception to Stark Law and increasing federal program costs.
Skeptical that the GAO study alone mitigates incentives for overprescribing or waste.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Technically specific and time‑limited, improving prospects, but contested interests and uncertain fiscal impacts reduce overall likelihood.
The bill has not accumulated any surfaced votes yet.
Access and convenience versus conflict‑of‑interest and cost concerns
Technically specific and time‑limited, improving prospects, but contested interests and uncertain fiscal impacts reduce overall likelihood.
Relative to its intended legislative type, this bill is a clearly drafted substantive amendment that establishes a time-limited exception to the physician self-referral prohibition for certain Part D drugs, with detaile…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.